No. “PRP” describes a broad category, not a single standardized product.

Platelet-rich plasma can differ substantially depending on the amount of blood collected, centrifugation method, platelet concentration, leukocyte content, red blood cell contamination, final treatment volume, and how the sample is handled before injection.

Two treatments may both be called PRP while delivering very different biologic preparations.

At Alypos, PRP is prepared according to the tissue being treated and the clinical objective rather than by assuming one fixed preparation is appropriate for every patient.

No. A commercial kit standardizes equipment, but it does not replace physician judgment.

Kits vary in the amount of blood processed, platelet recovery, leukocyte concentration, final volume, and degree of red blood cell separation. A fixed kit protocol may also produce the same preparation regardless of whether the physician is treating cartilage, tendon, ligament, or another structure.

At Alypos, preparation variables are physician-directed and adjusted according to the patient, tissue, and treatment plan rather than determined solely by a prepackaged system.

Because the preparation process influences what is ultimately delivered to the treatment site.

Dr. Bernhardt controls the blood volume collected, centrifugation strategy, separation of cellular layers, final concentration, and treatment volume. When clinically appropriate, a double-spin process may be used to provide greater control over the final preparation.

The goal is not simply to produce “PRP.” It is to prepare a biologic that is appropriate for the structure being treated while minimizing components that may be undesirable in that setting.

They may matter, but more is not automatically better.

Platelet concentration, leukocyte content, red blood cell contamination, and final injectate volume can influence the biologic environment created after treatment.

Different tissues may call for different preparation characteristics. A preparation intended for a chronically injured tendon may not be identical to one selected for an arthritic joint.

Alypos does not rely on a universal concentration target or assume that the preparation with the highest platelet count is necessarily the most appropriate.

PRP cannot help a structure it does not reach.

Accurate treatment requires more than injecting near the general area of pain. Ultrasound guidance allows the physician to visualize the intended joint, tendon, ligament, fascia, or other anatomical structure and confirm precise needle placement during the procedure.

At Alypos, image guidance is integrated with the examination and diagnostic findings so the biologic is delivered to a clearly defined target rather than injected according to symptoms alone.

No. Pain location does not always identify the structure causing the symptoms.

Joint pain, tendon injury, ligament instability, nerve irritation, and referred pain can overlap. Injecting PRP into the most painful location without first establishing the likely source of symptoms may result in treating the wrong structure.

At Alypos, treatment begins with a physician evaluation, review of imaging, and focused ultrasound assessment when appropriate. PRP is considered only after the intended target and clinical rationale have been established.

Not automatically.

Predetermined injection packages may be convenient, but they do not account for differences in diagnosis, tissue quality, severity of injury, or individual response.

For many patients, Alypos begins with a single carefully planned treatment and allows adequate time for biologic response before deciding whether another procedure is justified.

Additional treatment is recommended only when the patient’s response and clinical circumstances support it.

Both platelet-rich plasma and platelet-rich fibrin are prepared from the patient’s own blood, but they differ in processing and physical characteristics.

PRP is generally prepared as an injectable liquid containing concentrated platelets and associated signaling factors. PRF is processed differently and forms a fibrin-based matrix that may be useful in selected clinical settings.

Alypos does not treat PRP and PRF as interchangeable products. The choice depends on the tissue, treatment objective, and physician’s judgment.

No regenerative procedure can guarantee a specific outcome.

PRP may support tissue signaling, healing, and recovery in appropriately selected patients, but response varies according to diagnosis, tissue quality, age, health, mechanical loading, and rehabilitation.

PRP cannot reliably correct severe mechanical instability, replace absent tissue, reverse every degenerative change, or compensate for an incorrect diagnosis or inaccurate injection.

The biologic is only one part of treatment. Patient selection, preparation quality, precise delivery, and appropriate recovery all influence the opportunity for improvement.